与 APOE 基因型相关的体力活动、阿尔茨海默病和认知 (PAAD-2)
身体活动对与 APOE 基因型相关的认知的影响 (PAAD-2)
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
North Carolina
-
Greensboro、North Carolina、美国、27402
- University of North Carolina-Greensboro
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
- 阿尔茨海默病家族史,认知障碍
- 能用英语沟通
- 目前未达到体育锻炼建议(建议每周锻炼 3 天,每天锻炼 30 分钟以上,持续时间超过 3 个月)
- 愿意随机分配到任一研究条件
- 愿意完成一年的所有学习活动
排除标准:
- 符合临床认知障碍标准
- 由于已知的心血管、代谢或肾脏疾病并且有症状或由于骨科限制而无法进行身体活动
- 自我报告混杂的神经系统、精神病或活动性严重或功能失能的神经系统或医学疾病的历史,或任何其他可能限制运动或对患者构成危险的情况
- 当前使用药物治疗阿尔茨海默病的症状,对认知产生不利影响,或影响心率
- 使用流行病学研究中心抑郁量表的简短形式满足抑郁症的标准
- 在研究过程中长时间旅行(> 1 个月)
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:身体活动状况 (PAC)
受试者将被要求每周参加 3 次虚拟锻炼课程,持续 1 年。
|
受试者将参加为期 1 年的每周 3 次虚拟小组锻炼课程。
根据静息心率和年龄,鼓励每位受试者以中等强度(目标心率 (HR) = 40-59% 心率储备)行走。
受试者将自己进行有氧运动,阻力运动将在教练的虚拟锻炼课程中完成,每天 1 小时,每周 3 天,持续 1 年。
在锻炼课程中,这些参与者将被要求记录已完成锻炼的测量值,并可能被要求提供心率测量值(通过触诊 20 秒评估)和自觉运动率 (RPE)。
他们将被要求提交提供此信息的练习日志。
将审查来自运动日志和运动专家记录的数据,以获取进展证据、持续达到中等强度,以及有氧和力量训练部分的规定持续时间。
|
|
无干预:常规护理控制 (UCC)
常规护理控制的参与者将保持其正常健康习惯 1 年。
参与者将收到每两周一次的健康时事通讯,并将每两周联系一次以回答任何问题并询问参与者的健康状况。
参与者自我报告的身体活动将每月评估一次。
以这种方式,工作人员每周都会联系参与者。
完成所有研究相关活动(包括测试前、中期和测试后)的常规护理控制参与者将在测试后获得短期 YMCA 会员资格。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With Stroop Interference Reaction Time (RT)
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on Stroop Interference.
Stroop interference is calculated using reaction time (RT) data from correct trials and the following formula: Stroop Interference RT = Stroop Incongruent RT - (average (Stroop Congruent RT , Stroop Neutral RT)).
Stroop Congruent is also known as Stroop Word, and Stroop Neutral is also known as Stroop Color.
RT is recorded in msec and a larger score is indicative of greater interference (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With Trail Making Test Interference
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Comprehensive Trail Making Test (TMT) interference.
TMT interference is calculated as total time to complete TMT B (also called Trail 5) minus the total time to complete TMT A (also called Trail 1)which were both recorded in seconds.
TMT interference is, therefore, recorded in seconds with a larger score indicative of greater interference (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With NIH Toolbox Dimensional Change Card Sort
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the NIH Toolbox Dimentional Change Card Sort Test (DCCS).
We used the recommended outcome of the DCCS computed score.
This is calculated automatically within the NIH Toolbox based upon a two-stage process combining a score of 0-5 from the accuracy data with a score of 0-5 from the reaction time data.
Thus, scores range from 0-10 with a higher score indicative of better performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With the NIH Toolbox Flanker Test.
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the NIH Toolbox Flanker Inhibitory Control and Attention Test.
We used the recommended outcome of the Flanker computed score.
This is calculated automatically within the NIH Toolbox based upon a two-stage process combining a score of 0-5 from the accuracy data with a score of 0-5 from the reaction time data.
Thus, scores range from 0-10 with a higher score indicative of better performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Memory as Measured With the Auditory Verbal Learning Test.
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Auditory Verbal Learning Test.
Majdan et al. (1996) Form 1 was given at pre, the standard Rey Auditory Verbal Learning list was given at mid, and Majdan et al. (1996) Form 2 was given at post.
These versions are comparable in terms of their scores (Sherman, Tan, & Hrabok, 2022).
Possible scores range from 0-15 with a bigger score being indicative of better memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Memory as Measured With the Rey-Osterrieth Complex Figure Test
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Rey Osterreith Complex Figure Test.
Tests were scored using the deep learning approach for automated scoring published by Langer et al. eLife 2024;13:RP96017.
DOI: https://doi.org/10.7554/eLife.96017.
Possible scores range from 0-36 with higher scores being indicative of better memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Memory as Measured With the NIH Toolbox Picture Sequence Test
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the NIH Toolbox Picture Sequence Memory Test - The computed score is an IRT-based theta score of the number of adjacent pairs placed for trial 1 and 2 with a higher score being indicative of better memory.
This score is automatically created within the NIH Toolbox.
Version A was given at pre, Version B was given at mid, and Version C was given at post.
Possible scores range from 200-700 with a higher score being indicative of better performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Memory as Measured With the Mnemonic Similarity Test
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) Lure Discimination Index (LDI) on the Mnemonic Similarity Test (MST).
The MST was created based upon the publicly available and validated instructions and stimuli provided by the creators of the task (Stark, Kirwan, & Stark, 2019).
Equivalent versions of the test are administered so participants see different stimuli at each testing session and those stimuli were counterbalanced to rotate through the different item types.
The formula for calculating the LDI is: p(similar|lure) - p(similar|foil) where p(similar|lure) = Total # of "similar" responses to lure items / 36 and p(similar|foil) = Total # "similar" responses to foil items / 36.
Scores range from -1 to +1 with a larger score indicating better discrimination performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Attention as Measured With the Paced Auditory Serial Addition Test
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in attention will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the 2-sec trial of the Paced Auditory Serial Addition Task.
Scores are reported as the number of correct responses with possible scores ranging from 0-60 and larger scores being indicative of better attention.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Attention as Measured With the Forward Digit Span Test
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in attention will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Neurological Assessment Battery (NAB) Digit Span Forward test.
Scores are reported as the number of correct trials with possible scores ranging from 0-14 and larger scores being indicative of better attention.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Working Memory as Measured With NIH Toolbox List Sort Working Memory
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in working memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the NIH Toolbox List Sort Working Memory Test.
Scores are reported as the sum of the total number of items correctly recalled and sequenced on Lists 1 and 2 with possible scores ranging from 0-26 and larger scores being indicative of better working memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Working Memory as Measured With Spatial Working Memory
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in working memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) reaction time on the 4-dot trial of the Spatial Working Memory Test.
Scores are reported as the average reaction time (RT) for correct responses.
Smaller scores are indicative of faster performance (i.e., better performance).
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Working Memory as Measured With Backward Digit Span
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in working memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) accuracy on the Neurological Assessment Battery (NAB) Digit Span Backwards test.
Scores are reported as the number of correct trial with possible scores ranging from 0-14 and larger scores being indicative of better working memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Processing Speed as Measured With the Digit Symbol Modalities Test (SDMT)
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in working memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Digit Symbol Modalities Test (SDMT) (Smith, 1973).
Scores are reported as the sum of Oral and Written Trial Raw Scores (correct responses) with possible scores ranging from 0-220 and larger scores being indicative of better working memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Processing Speed as Measured With the Stroop Word Test
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in processing speed will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on Stroop Word condition (also known as the Stroop Congruent condition).
RT is recorded in msec and a larger score is indicative of slower performance (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Processing Speed as Measured With the Stroop Color Test
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in processing speed will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on Stroop Color condition (also known as the Stroop Neutral condition).
RT is recorded in msec and a larger score is indicative of slower performance (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Processing Speed as Measured With the Trail Making Test A
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Comprehensive Trail Making Test (TMT) A (TMT A) (also known as Trail 1).
Performance is recorded in seconds with a larger score indicative of slower performance (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With Matrix Reasoning.
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on Matrix Reasoning Accuracy from the Virginia Cognitive Aging Project (VCAP).
Version O was given at pre, Version A was given at mid, and Version B was given at post.
Possible scores are proportions that range from 0-1 (i.e., 0% accuracy to 100% accuracy expressed on a 0.00-1.00
scale) with a higher score being indicative of better performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Brain Morphology (Whole Brain Volume)
大体时间:Pre-Test and Post-Test (~12 months)
|
Change in whole brain morphology will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) for total segmented brain volume (i.e., total brain separated from non-brain structures).
This is measured as volume (mm3), with volumes ranging from 1,050,000 to 1,350,000, and with higher values being interpreted as better.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Morphology (Left Hippocampus Volume)
大体时间:Pre-Test and Post-Test (~12 months)
|
Change in Left Hippocampus Volume will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) for total segmented left hippocampus volume (i.e., left hippocampus segmented away from other regions).
This is measured as volume (mm3), ranges from 2500 to 4500, and higher values are better.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Morphology (Right Hippocampus Volume)
大体时间:Pre-Test and Post-Test (~12 months)
|
Change in Right Hippocampus Volume will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) for total segmented right hippocampus volume (i.e., right hippocampus segmented away from other regions).
This is measured as volume (mm3), ranges from 2500 to 4500, and higher values are better.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - BDNF
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - Irisin
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - IGF-1
大体时间:Pre-Test and Post-Test (~12 months)
|
Change in blood biomarkers (BDNF, irisin, IGF-1, glucose, insulin, TNF-⍺, serum amyloid protein (SAP), albumin, ApoE and ⍺-2 macroglobulin) - IGF-1. Blood samples will be taken following a 12-hour fast. Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin. Change from pre-test to post-test will be assessed. The capture antibodies in the kits we received from the company for IGF-1 were not effective. We attempted to secure new kits to conduct the assays, but did not receive the kits in a timely fashion. We intend to conduct these assays upon receipt of the kits and the availability of personnel to perform the assays. The anticipated reporting date for IGF-1 is January 2027. |
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - Glucose
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - Insulin
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - TNFa
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - SAA
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - ALB
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - ApoE
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - ⍺-2 Macroglobulin
大体时间:Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Cardiorespiratory Fitness
大体时间:Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Fitness will be assessed by comparing predicted VO2max at Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months).
Fitness will be assessed using a submaximal graded aerobic exercise test performed on a treadmill.
Oxygen uptake (VO2) at each stage is estimated based on the treadmill speed and grade during a ramped exercise protocol performed until volitional exhaustion or test termination due to symptom limitations.
The VO2max estimation uses the slope of the regression line between the heart rates (HR) of the last two stages to extrapolate to the participant's predicted VO2 at their age-predicted max HR (220-age).
If HR at either of the last two stages is <110, VO2 could not be reliably calculated, and we consider the participant to have insufficient data (ID).
We have explored other options for estimating VO2 max, but believe this is the best option available.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Right Lateral Parietal, Posterior Cingulate Cortex
大体时间:Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Left Lateral Parietal, Right Lateral Parietal
大体时间:Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Left Lateral Parietal, Posterior Cingulate Cortex
大体时间:Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Medial Prefrontal Cortex, Posterior Cingulate Cortex
大体时间:Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Medial Prefrontal Cortex, Right Lateral Parietal
大体时间:Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Medial Prefrontal Cortex, Left Lateral Parietal
大体时间:Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
合作者和调查者
调查人员
- 首席研究员:Jennifer Etnier, PhD、UNC Greensboro
出版物和有用的链接
一般刊物
- Park KS, Etnier JL. An innovative protocol for the artificial speech-directed, contactless administration of laboratory-based comprehensive cognitive assessments: PAAD-2 trial management during the COVID-19 pandemic. Contemp Clin Trials. 2021 Aug;107:106500. doi: 10.1016/j.cct.2021.106500. Epub 2021 Jul 2.
- Park KS, Ganesh AB, Berry NT, Mobley YP, Karper WB, Labban JD, Wahlheim CN, Williams TM, Wideman L, Etnier JL. The effect of physical activity on cognition relative to APOE genotype (PAAD-2): study protocol for a phase II randomized control trial. BMC Neurol. 2020 Jun 6;20(1):231. doi: 10.1186/s12883-020-01732-1.
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 18-0228
- R01AG058919 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
数据文档和去识别化的数据将按照适用的法律法规进行存储以供共享。 数据将以去识别化匿名状态和 .csv 格式提供 格式。 数据将通过将数据从 RedCap 导出到 .csv 来共享 北卡罗来纳州格林斯博罗大学 (UNCG) 大学图书馆机构资料库北卡罗来纳州数字在线知识和奖学金 (NC DOCKS) 的研究主要调查员的机构概况下存档的文件。
这些数据还将通过全球阿尔茨海默氏症协会互动网络 (GAAIN) 共享,这是一个联合数据系统,旨在促进数据共享,并为对阿尔茨海默氏症相关数据感兴趣的研究人员开展合作。 感兴趣的科学家可以探索 PAAD-2 和其他研究的元数据。 通过成为合作伙伴,将在 www.gaain.org 上提供 PAAD-2 的描述和联系主要研究者的链接。
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.